Kymera Therapeutics, Inc.KYMRNASDAQ
Loading
EV to Sales: Premium ValuationElevated
Percentile Rank86
3Y CAGR+79.7%
5Y CAGR+14.7%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
+79.7%/yr
Annual compound
5Y CAGR
+14.7%/yr
Recent acceleration
Percentile
P86
Within normal range
vs 5Y Ago
2x
Strong expansion
Streak
2 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 160.50 | +153.0% |
| 2024 | 63.45 | +241.4% |
| 2023 | 18.59 | -32.8% |
| 2022 | 27.66 | -33.2% |
| 2021 | 41.42 | -48.7% |
| 2020 | 80.79 | -83.4% |
| 2019 | 486.10 | - |
| 2018 | 0.00 | - |